Filing Flows › Usana Health Sciences (USNA) › Q2 2026
Usana Health Sciences (USNA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Usana Health Sciences (USNA) reported revenue of $223M for the second quarter 2026 (Q2 2026), -5% from a year earlier and -11% from the quarter before. Operating margin was -9.0%, net loss $28.0M (12.5% of revenue).
Usana Health Sciences, Q2 2026: revenue $223M (-5% year over year), operating margin -9.0%, net loss $28.0M, operating cash flow $23.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $223M | -11% | -5% |
| Operating profit | −$20.0M | -244% | -220% |
| Net earnings | −$28.0M | -472% | -389% |
| Operating cash flow | $23.3M | +139% | +91% |
| Free cash flow | $20.2M | +183% | +180% |
What changed
Revenue was $223.3M in Q2 2026, down 5% year over year and down 11% from the previous quarter.
Gross margin was 78.3%, down 0.4 points from Q2 2025. Operating costs exceeded revenue by $20.0M, an operating margin of -9.0%. Operating expenses grew 15% against a revenue fall of 5%. The fastest-growing cost line was Other operating costs (+29%). The quarter ended with a net loss of $28.0M, after a profit of $7.0M the previous quarter. Minority interests bore $6.6M of it: to shareholders the quarter was a loss of $21.4M.
Operating cash flow was $23.3M (up 91% year over year). Non-cash charges added back $7.7M of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items added $40.2M. Capital expenditures of $3.2M left free cash flow of $20.2M.
Questions
What was Usana Health Sciences' revenue in the second quarter 2026?
Usana Health Sciences (USNA) reported revenue of $223M for the second quarter 2026 (Q2 2026), -5% from a year earlier and -11% from the quarter before.
Was Usana Health Sciences profitable in the second quarter 2026?
Operating loss was $20.0M (-9.0% of revenue) and net loss $28.0M.